A multicenter phase 2 randomized controlled study on the efficacy and safety of reparixin in the treatment of hospitalized patients with COVID-19 pneumonia

G Landoni, L Piemonti, AA Monforte, P Grossi… - Infectious diseases and …, 2022 - Springer
Introduction Acute lung injury and acute respiratory distress syndrome are common
complications in patients with coronavirus disease 2019 (COVID-19). Poor outcomes in …

Redox stress in COVID-19: Implications for hematologic disorders

M Yang - Best Practice & Research Clinical Haematology, 2022 - Elsevier
COVID-19 is the respiratory illness caused by the beta coronavirus SARS-CoV-2. COVID-19
is complicated by an increased risk for adverse thrombotic events that promote organ failure …

[PDF][PDF] A Multicenter Phase2 Randomized Controlled Study on the Efficacy and Safety of Reparixin in the Treatment of Hospitalized Patients with COVID-19 …

PGAZE Bucci, M Allegretti, GGEMG Neal, PM De Pizzol… - 2022 - air.unimi.it
Introduction: Acute lung injury and acute respiratory distress syndrome are common
complications in patients with coronavirus disease 2019 (COVID-19). Poor outcomes in …